Member Info for Thompi

Agree Dibs, there is no comparison to POLX. I hold POLX but took last Thursday’s “contagion” dip as an opportunity to make a modest top up in AGL, but I appreciate it must be very frustrating to the majority of AGL investors.

Sorry not to have provided a link, they don’t always work for me and there is too much detail to paste the whole thing.
The important bit is that AN has 1,000,000 options due to expire 17th November.
From the report “2) Vesting is subject to a) the performance conditions that (i) the Company’s share price must have increased to £2.00 at some point since the date of grant (this condition has not yet been met) and (ii) the Parsortix separation device must have been demonstrated to successfully capture circulating tumour cells from cancer patient blood (this condition has been met), and b) a service condition with options vesting over a three-year period (this condition has been met).

One thing is for sure, regardless of the options, we have a brilliant board and at some stage we will hopefully get the good news the company deserve.

AN & IG will want to hit the £2.00 mark by the 17th November in order to exercise their options (which are a tidy sum) before they expire on the 17th November. Source of info: AGL Annual Report December 2020 under remuneration section.
Hopefully FDA approval by then or other good news to act as an SP catalyst.

RNS hasn’t shown on here yet, but great to see POLX directors buying.

Morning Italian, in hindsight I should have taken some profit but POLX was & still is a conviction stock for me. I haven’t logged into my account, too depressing.
I’m going to hold. Nothing has changed with the potential, it’s just going to take longer than expected. Good luck whatever decisions you make.

Hi Goup, I am sitting on the sidelines wondering wether to reinvest or not. I dispiritedly cashed out at a big loss after AB handed in her notice.
I take your earlier point about DG & JH not selling up, and that is one of the things that may tempt me back. But there again the board haven’t exactly got much skin in the game, with the honourable exception of AR’s recent 4.7k buy. I suspect that many of the posters here have invested considerably more than that.
But I also think that AB would like go out with her reputation intact, and not with an SP that has halved during her tenure. So yes, I am tempted…GLA

Good move BOJO. I have been invested for a while now. I was out walking the dog when the news came through and could only watch in horror as the price crashed. Great opportunity to buy in. I haven’t added as I’m fully invested but am confident that we will eventually get FDA approval.
I am also invested in AGL which I think will have a very exciting future.

Agreed Barwickman, Ryan is a prolific poster, a lot of them disparaging other posters. We want new investors and we also want a balanced board. Half this board is taken up with bickering and it would be good to respect other view points and if you do disagree, don’t resort to name calling like “clowns” etc. It’s stuff you would expect to hear in the playground.

Good post BeContrarian.

Ryan, I think CF is a talented & genuine CEO. But I think his mouth runs away with him sometimes and it is damaging Orph’s credibility. Take a look at Wally’s notes. Yes deadlines slip through circumstances out of CF’s control and yes he is obviously trying to maximise the best price for the spin offs. But we are not talking weeks or a few months, we are probably talking the best part of a year with the exception of POLB.
I have very much bought into ORPH & CF but the share price has halved not doubled and that has got to be a concern.

Briggsie I agree that CF has made “promises’ in presentations that either haven’t actually happened or been delayed. I have watched countless presentations and a look back at some of Wallyj’s excellent notes from the meetings are a reminder of just how much. Take for example, 17 September 2020. I understand deadlines can slip, but bear in mind CF is talking about Xmas 2020. I am a LTH but I am finding the SP continuous slide very frustrating.

Excerpts of Wally’s notes 17/9/20

CF
- Reiterated aim of 50% SP growth every 6 months or 100%

- World's largest database of disease progression data, getting interest from wearable health tracker manufactuters. ORPH is actively working with them, expecting to announce before the end of the year a licensing deal for this data with one of the big players - approach from wearables manufacture was unexpected

- Expecting significantly higher cash balance at Christmas. Any excess cash will be handed back to shareholders

-Imutex - any update in last couple of months? what is the most likely scenario, i.e. cash sale or Nasdaq listing?
--- 6 month process from July, aiming for before Christmas for outcome.

How many of existing 10k records are available on database for interested parties to purchase?
--- "Vastly more than 10k" records available. 5 biggest companies in wearable space have been invited to bid - highest bidder obviously wins. Guideline for pre-Christmas for "very positive" announcement here. The aim is to keep generating as much additional revenue from database beyond wearable licensing. CF was very optimistic regarding the potential.

Any updates on Prepbio?
--- Work in progress, 64% ownership for ORPH, looking for disposal by Xmas

Thanks Alphageddon, that was my take too. As you say, definitely worth a listen.

I don’t mind JW. Clearly he has an agenda and I agree his valuations can be over enthusiastic. But to be fair he did a good interview with RH and can provide a good source of info, albeit you have to take some of what he says with a big dose of salt. Probably wouldn’t buy a used car off him though…
Ultimately my decisions, my responsibility. Hope we get good news soon. ATB

Agree Deepjoy “rewards come with risk but the biggest rewards come with patience and bottle”.
I have been tempted to de-risk and take some profit, and POLX has done really well for me, but I have held firm. This is a conviction stock for me.
Hope we get good news soon and that I have made the right decisions. GLA

Interesting post DonJules and replies Ed & Leyedman. I’m sitting on a 90% loss and made a bad judgement in not selling once the bad news hit.
I take your point about the demand for potash. Too late for me to sell now, so I will hang on and see what happens. Not sure if I want to commit further funds, once bitten twice shy etc. Hopefully your strategy will come good and in a few months will prove to be a really good decision. GLA

I initially invested in ORPH through a broker on their recommendation in May 2020. I have since added various top ups in my SIPP, most of them in the red.
The SP drift is frustrating, and I have to remind myself that I have to look at in the context of ORPH being a long term investment.
I spoke to my broker yesterday. In his opinion institutions do not like the lock in period of the spin outs for their clients. Not all clients understand them, it causes due diligence problems, and are awkward to hold.
Anyhow GLA and hopefully the tide will turn for the better.

I invested in the TB Amati UK Smaller Companies fund for a similar reason. Amati, as we know, have a significant stake in POLX, particularly in their VCT.
Amati also invest in a couple of other shares I’m interested in (AGL & RENX) and I like the fact that I have more exposure to these stocks, but also that the risk is diluted by the fund holding other investments.
Thanks for the IIG suggestion, I am in the process of reading up about it.

“ Tissue Regenix (AIM: TRX), the regenerative medical devices company, announces that on 23 September 2021, Brian Phillips, Non-executive director, acquired 9,000,000 Ordinary Shares in the Group at a price of 0.6081 pence per share for a total consideration of £54,729.00.”
Way to go Brian, nice one!

I agree with all your comments Dan, The Italian & Mavern. To me it was a measured and professional interview and I was reassured, which I thought maybe one of the purposes of the interview - to calm any jitters?
Hope you are wrong Maestro and that the “continuous back & forth” communication with the FDA will negate any requests for additional information, but who knows. Not long now to find out.

I’ve added today too a small top up at 85.26p. Can’t for the life of me understand the sluggish SP.

Richard was asked the question “are there clinical applications beyond pulmonary disease that Polarean could have potential applications in?” The reply was yes - in cardiology, an area that RH has mentioned before.

So much potential. I am genuinely excited for the future, albeit with a few nerves as I have, by my standards, sunk a bit of cash in. GLA